Company Overview and News
KUALA LUMPUR (Oct 18): CIMB IB Research said Telekom Malaysia Bhd could be excluded as a constituent stock while Top Glove Corp Bhd may be added when FTSE Russel announces the outcome of ist semi-annual review of the FBM KLCI constituents on Dec 6 this year.
TGLVY 4863 7113 TPGVF MYTEF 5246 GEBHF 7277
KUALA LUMPUR (Oct 16): Telekom Malaysia Bhd (TM) said it looks forward to a collaborative win-win approach with the government to effectively address challenges faced by customers of TM's Internet service Streamyx once and for all.
KUALA LUMPUR (Oct 16): Top Glove Corp Bhd shares rose as much as 46 sen or 4.1% to RM11.68 so far today after the company said yesterday the Employees Provident Fund (EPF) and Retirement Fund (Inc) acquired Top Glove shares last week.
TGLVY 4863 7113 TPGVF MYTEF BSMAF 1818
KUALA LUMPUR (Oct 16): Affin Hwang Capital Researhc has maintained its “Sell” rating on Telekom Malaysia Bhd (TM) at RM2.60 with a lower target price of RM2.25 (from RM3) in view of intensifying competition, declining ARPUs, weaker profitability and a rising risk premium.
TELEKOM Malaysia Bhd (TM), whose share price has been on the decline since the Pakatan Harapan government took over in May, saw no respite last week. It slid further to close at RM3.08 on Friday, which translates into a year-to-date decline of 50% or a market cap loss of RM12.1 billion. Just a day before the May 9 national polls, it was trading at RM5.
4863 5347 TNABY MYTEF TNABF BSMAF 1818
KUALA LUMPUR (Oct 11): Maxis Bhd wants to be a price maker in the telco sector, and not a price taker as is commonly perceived of cellular network service providers.
Selling pressure on the local market gained strength following a slew of announcements by the government, from greater competition in the telecommunications sector to the termination of MMC Gamuda KVMRT (T) Sdn Bhd’s contract for the mass rapid transit Line 2 (MRT2) and introduction of new taxes.
GMALY 1562 4863 5347 4715 GMALF 6888 TNABY AXXTF MYTEF TNABF GEBHF
Market meltdown: The benchmark FBM KLCI fell the most in nearly five months and recorded the fourth-largest intra-day decline year-to-date against the backdrop of foreign funds selling out. — AP
4863 5347 6888 TNABY AXXTF MYTEF TNABF BSMAF GEBHF 3719 1818
KUALA LUMPUR, Oct 10 — Share prices ended sharply lower across the board on Bursa Malaysia today due to a mix of local and external factors as investors, among others, cautiously digested government plans to introduce new taxes to reduce its debt obligation.
4863 PBLOF 5819 7036 MYTEF 1295 BSMAF HIPEF 1818 5199
KUALA LUMPUR (Oct 10): The FBM KLCI fell 38.97 points or 2.2% as anticipation that the Government will devise new taxes and sell assets to reduce debt affected market sentiment.
4863 5347 6888 TNABY AXXTF MYTEF TNABF GEBHF
KUALA LUMPUR (Oct 10): Axiata Group Bhd, Telekom Malaysia Bhd (TM) and Genting Bhd were the three biggest laggards among the FBM KLCI component stocks in the afternoon session.
GMALF 5168 6033 7277 CIMDF GMALY 1023 PNADF 4863 5347 4715 TNABY 6888 AXXTF MYTEF TNABF PNAGF GEBHF HRGHY
TIME dotCom Bhd (Oct 8, RM8) Maintain buy with an unchanged target price of RM9.30: TIME dotCom Bhd has launched the lowest priced 100Mbps plan in the market at RM99 per month. This is 34% below the previous RM149 package for the same speed, and undercuts similar offerings by both Telekom Malaysia Bhd (TM) and Maxis Bhd. TIME has also unveiled a 1Gbps plan at RM199 per month, which is a first in the country, and surpasses TM’s 800Mbps plan.
KUALA LUMPUR (Oct 8): Communications and Multimedia Minister Gobind Singh Deo said today the recent reduction of broadband prices by the telecommunications companies (telcos) doesn't apply to their existing customers.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET